Testing RAG-01 for bladder cancer that returned after BCG treatment
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug, RAG-01, for people with a type of bladder cancer called non-muscle-invasive bladder cancer (NMIBC) that has come back after BCG therapy. The drug is given through a catheter into the bladder, and the study aims to see if it can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have high-grade NMIBC (grade 2 or 3) that has come back after BCG treatment
- Your overall health is good enough to likely live at least 6 more months
- You can tolerate having a catheter placed in your bladder
- Your kidney, liver, and blood cell counts are within certain ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, RAG-01, given alone or with chemotherapy, for people with a type of bladder cancer that hasn't spread into the muscle. The goal is to see if it can help treat the cancer and if it's safe.
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
This study tests an experimental medicine called UGN-501 given directly into the bladder. It is for people whose bladder cancer has come back despite previous treatments, such as BCG therapy. The goal is to find the best dose and see how safe and effective it is.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
This trial tests a new form of intravesical (given directly into the bladder) treatment called rMBCG for people with non-muscle invasive bladder cancer who have not had BCG therapy before. It may be an option for those with certain types of early bladder cancer, including carcinoma in situ (CIS) or papillary tumors after removal surgery.
This trial tests whether a new bladder cancer drug (SHR-1501) works alone or combined with BCG, and compares options with another drug (SHR-1316), in people with high-risk non–muscle-invasive bladder cancer. It may help reduce cancer coming back and improve control of the disease.
Hear when a new Non-Muscle-Invasive Bladder Cancer (NMIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.